Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of pirtobrutinib versus investigator's choice BTK inhibitor in previously treated BTK inhibitor-naive mantle cell lymphoma
MOH_2021-09-08_010244Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by Loxo Oncology. Started Aug 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on MOH_2021-09-08_010244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-08_010244.